-
Parnax Lab Limited Announces Positive Results from Phase 2 Trial of PNX-2001 in Patients with Advanced Solid Tumors
Parnax Lab Limited (NASDAQ: PRNX), a clinical-stage biopharmaceutical company ... Positive Phase 2 Data for PNX-2001 in Advanced Solid Tumors.
-
Parnax Lab Limited Announces Pricing of Initial Public Offering
MENLO PARK, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Parnax Lab Limited (the ... announced the pricing of its initial public offering of 7,000,000 American Depositary Shares (ADSs), each representing one ordinary share of the Company.
-
Parnax Lab Announces Initiation of Phase 2 Trial of PNX-2001 in Patients with Advanced Solid Tumors
MENLO PARK, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Parnax Lab Limited (the “Company” or “Parnax”) (NASDAQ: PRNX), a clinical-stage biopharmaceutical company pioneering the discovery and development of novel ...
-
Parnax Lab Limited Announces FDA Clearance of IND Application for PNX-2001 in Advanced Solid Tumors
MENLO PARK, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Parnax Lab Limited (the “Company” or “Parnax”) (NASDAQ: PRNX), a clinical-stage biopharmaceutical company pioneering the discovery and development of novel oral small molecule therapies for the treatment ...
-
Parnax Lab, a leader in bioanalytical testing, has become the first lab in the state of Texas to receive the ISO 17025:2017 certification.
This certification is a globally recognized standard for quality and competence in testing and calibration laboratories. It demonstrates that Parnax Lab meets the highest international standards for accuracy, reliability, and impartiality in its testing services.
-
Parnax Lab has announced the launch of its new state-of-the-art laboratory in Houston, Texas.
The new lab is equipped with the latest technology and instrumentation, and it will allow Parnax Lab to expand its testing capabilities and meet the growing demand for its services.
-
Parnax Lab has been awarded a contract by the National Institutes of Health (NIH) to provide bioanalytical testing services for a clinical trial.
This is a major win for Parnax Lab, and it is a testament to the quality of its services and its reputation as a leader in the field of bioanalytical testing.
-
Parnax Lab Limited Announces Positive Phase 2a Results for PARN-2001 in Atrial Fibrillation
Parnax Lab Limited (Parnax) today announced positive results from a Phase 2a study of its lead drug candidate, PARN-2001, in patients with paroxysmal atrial fibrillation (AF). The PARN-2001 is a potent and selective inhibitor of the NaV1.5 sodium channel, which is known to play a critical role in the initiation and maintenance of AF.
-
Parnax Lab Limited Raises $50 Million in Series B Financing to Advance PARN-2001 Development
Parnax Lab Limited (Parnax) announced today that it has raised $50 million in a Series B financing round. The financing was led by new investor Vivo Capital, with participation from existing investors Domain Associates and Arch Venture Partners.
-
Parnax Lab Limited Receives FDA Orphan Drug Designation for PARN-2001 in Atrial Fibrillation
Parnax Lab Limited (Parnax) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to PARN-2001 for the treatment of atrial fibrillation (AF).